TREM2 Modulator Compounds for Restoring Microglial Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a high unmet medical need for modulators of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) to address neurodegenerative diseases such as Alzheimer's disease, Frontotemporal lobar degeneration, Parkinson's disease, Huntington disease, Nasu-Hakola disease, Multiple sclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathies, and Amyotrophic lateral sclerosis, as loss-of-function variants of TREM2 are associated with these conditions.
Innovation Solution
Development of compounds that modulate TREM2 activity, specifically targeting the extracellular part of the receptor, including various substituted pyrimidines and pyridines, to restore functional microglial responses and mitigate neurodegenerative disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TREM2 activity is not modulated, then microglial response remains blunted in loss-of-function variants, but neurodegenerative disease progression continues unchecked
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to TREM2 receptor and activate its signaling pathway. These compounds serve as mediators between the TREM2 receptor and downstream signaling molecules (DAP12, Syk kinase), restoring the blunted microglial response without requiring genetic correction of loss-of-function variants. The compounds facilitate signal transduction by stabilizing TREM2 in an active conformation or enhancing its interaction with ligands and co-receptors.
Solution Approach 2:
The patent modifies the functional parameters of TREM2 receptor by introducing exogenous compounds that alter its signaling activity. The compounds change the activation threshold, signal amplitude, and duration of TREM2-mediated signaling pathways. This parameter modulation restores microglial responsiveness to pathological stimuli without changing the underlying genetic defect, effectively compensating for loss-of-function variants through pharmacological parameter adjustment.
2Productivity
If TREM2 signaling is enhanced to improve microglial function, then phagocytosis of cellular debris increases, but risk of off-target effects and toxicity may increase
Solution Approach 1:
The patent achieves selective enhancement of TREM2 signaling by designing compounds with high specificity for the TREM2-DAP12 complex. The local quality of the interaction is optimized through structure-activity relationship studies that identify molecular features conferring selectivity. This ensures that TREM2 modulation occurs specifically in microglia expressing both TREM2 and DAP12, minimizing off-target effects in other cell types or through non-specific mechanisms.
Solution Approach 2:
The patent incorporates feedback mechanisms where TREM2 activation leads to downstream signaling events that can be monitored to assess appropriate dosing and therapeutic response. The signaling cascade (TREM2-DAP12-Syk- downstream pathways) provides intrinsic feedback that limits excessive activation, and this natural regulatory mechanism is preserved while enhancing baseline activity. This feedback control helps prevent toxic overactivation while maintaining improved phagocytic function.
Data Source
AI summary
The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells-2 (“TREM2”). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as neurodegenerative diseases, and to pharmaceutical compositions comprising the compounds.